The 25 references in paper A. Tatarsky R., А. Татарский Р. (2014) “ДИАГНОСТИКА, ДИФФЕРЕНЦИАЛЬНАЯ ДИАГНОСТИКА И ЛЕЧЕНИЕ БРОНХООБСТРУКТИВНОГО СИНДРОМА: МЕСТО КОМБИНИРОВАННЫХ ПРЕПАРАТОВ Β2-АГОНИСТОВ И ИНГАЛЯЦИОННЫХ ГЛЮКОКОРТИКОСТЕРОИДОВ // DIAGNOSIS, DIFFERENTIATION AND MANAGEMENT OF BRONCHIAL OBSTRUCTIVE SYNDROME: A ROLE OF Β2-AGONISTS AND INHALED STEROIDS COMBINED IN A SINGLE INHALER” / spz:neicon:pulmonology:y:2011:i:1:p:89-98

1
Global initiative for asthma. Global Strategy for Asthma Management and Prevention Update 2009: www.gin asthma.org
(check this in PDF content)
2
Global initiative for chronic obstructive lung disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report / Last update 2009. www.goldcopd.org
(check this in PDF content)
3
Cazzola M., MacNee W., Martinez F.J. et al.Outcomes for COPD pharmacological trials: from lung functions to biomarkers. Eur. Respir. J. 2008; 31 (2): 416–469.
(check this in PDF content)
4
Chetta A., Zanini A., Foresi A. et al. Vascular component of airway remodeling in asthma is reduced by high dose of fluticasone. Am. J. Respir. Crit. Care Med. 2003; 167 (5): 751–757.
(check this in PDF content)
5
Hoshino M.Comparison of effectiveness in ciclesonide and fluticasone propionate on small airway function in mild asthma. Allergol. Int. 2010; 59 (1): 59–66.
(check this in PDF content)
6
Lundbäck B., Rönmark E., Lindberg A. et al.Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate. Respir. Med. 2006; 100 (1): 2–10.
(check this in PDF content)
7
Woolcock A.J., Bastiampillai S.A., Marks G.B., Keena V.A. The burden of asthma in Australia. Med. J. Aust. 2001; 175 (3): 141–145. Рис. 22. Взаимное влияние ХОБЛ и БА Примечание: синим цветом обозначены пациенты, у которых обструкция не полностью обратима; зона необратимой обструкции при БА связана с сочетанием БА и ХОБЛ. БАХОБЛ Сенсибилизирующий агентПатогенный агент Воспаление дыхательных путей, характерное для БА ПолностьюОграничение скоростиНе полностью обратимоевоздушного потокаобратимое Воспаление дыхательных путей, характерное для ХОБЛ Рис. 23. Характер бронхиальной обструкции при БА и ХОБЛ [2]
(check this in PDF content)
8
Bateman E.D., Boushey H.A., Bousquet J. et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am. J. Respir. Crit. Care Med. 2004; 170 (8): 836–844.
(check this in PDF content)
9
Mahler D.A. The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2002; 110 (6, Suppl.): S298–S303.
(check this in PDF content)
10
Mahler D.A., Wire P., Horstman D. et al.Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002; 166 (8): 1084–1091.
(check this in PDF content)
11
Vestbo J., Pauwels R., Anderson J.A. et al. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax 2005; 60: 301–304.
(check this in PDF content)
12
Vestbo J.New thinking and COPD. Ugeskr. Laeg. 2003; 165 (45): 4319.
(check this in PDF content)
13
Vestbo J.The TORCH (towards a revolution in COPD health) survival study protocol. TORCH Study Group. Eur. Respir. J. 2004; 24 (2): 206–210.
(check this in PDF content)
14
Calverley P.M., Anderson J.A., Celli B. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356 (8): 775–789.
(check this in PDF content)
15
Wedzicha J.A., Calverley P.M., Seemungal T.A. et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol / fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 2008; 177 (1): 19–26.
(check this in PDF content)
16
Jenkins C.R., Jones P.W., Calverley P.M. et al.Efficacy of salmeterol / fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir. Res. 2009; 10: 59.
(check this in PDF content)
17
Calverley P., Pauwels R., Vestbo J. et al.Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361 (9356): 449–456. Erratum in: Lancet 2003; 361 (9369): 1660.
(check this in PDF content)
18
Calverley P.M., Walker P. Chronic obstructive pulmonary disease. Lancet 2003; 362 (9389): 1053–1061.
(check this in PDF content)
19
Vestbo J., Pauwels R., Anderson J.A. et al.Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax 2005; 60 (4): 301–304.
(check this in PDF content)
20
Celli B.R., Thomas N.E., Anderson J.A. et al.Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am. J. Respir. Crit. Care Med. 2008; 178 (4): 332–338.
(check this in PDF content)
21
Calverley P.M., Anderson J.A., Celli B. et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010; 65 (8): 719–725.
(check this in PDF content)
22
Welte T. Inhaled corticosteroids in COPD and the risk of pneumonia. Lancet 2009; 374 (9691): 668–670.
(check this in PDF content)
23
Singh S., Loke Y.K. An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease. Int. J. COPD 2010; 5: 189–195.
(check this in PDF content)
24
Drummond M. B., Dasenbrook E.C., Pitz M.W. et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease a systematic review and meta-analysis. J.A.M.A. 2008; 300 (20): 2407–2416.
(check this in PDF content)
25
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ index.cfm Информация об авторе Татарский Алексей Романович– д. м. н., проф. кафедры госпитальной терапии педиатрического факультета РГМУ; тел.: (495) 465-52-64;
(check this in PDF content)